Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans ; volume:20 ; number:03 ; year:2021 ; pages:324-326
World Journal of Nuclear Medicine ; 20, Heft 03 (2021), 324-326
- Beteiligte Personen und Organisationen
-
Amoui, Mahasti
Ahmadi, Reyhane
Qutbi, Mohsen
Asli, Isa Neshandar
- DOI
-
10.4103/wjnm.wjnm_35_21
- URN
-
urn:nbn:de:101:1-2022051210381911398968
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Amoui, Mahasti
- Ahmadi, Reyhane
- Qutbi, Mohsen
- Asli, Isa Neshandar
Ähnliche Objekte (12)
![Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC](/assets/placeholder/searchResultMediaUnknown.png)
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Standardized image quality for 68Ga-DOTA-TATE PET/CT
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Standardized image quality for 68Ga-DOTA-TATE PET/CT
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Standardized image quality for 68Ga-DOTA-TATE PET/CT
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study